SG11201901889QA - An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy - Google Patents
An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathyInfo
- Publication number
- SG11201901889QA SG11201901889QA SG11201901889QA SG11201901889QA SG11201901889QA SG 11201901889Q A SG11201901889Q A SG 11201901889QA SG 11201901889Q A SG11201901889Q A SG 11201901889QA SG 11201901889Q A SG11201901889Q A SG 11201901889QA SG 11201901889Q A SG11201901889Q A SG 11201901889QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- novartis
- basel
- prevention
- oxazine derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16193770 | 2016-10-13 | ||
| PCT/IB2017/056281 WO2018069843A1 (en) | 2016-10-13 | 2017-10-11 | An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901889QA true SG11201901889QA (en) | 2019-04-29 |
Family
ID=57133087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901889QA SG11201901889QA (en) | 2016-10-13 | 2017-10-11 | An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10722518B2 (zh) |
| EP (1) | EP3525793A1 (zh) |
| JP (1) | JP2019534885A (zh) |
| KR (1) | KR20190068567A (zh) |
| CN (1) | CN109789145A (zh) |
| AU (1) | AU2017342207B2 (zh) |
| BR (1) | BR112019006591A2 (zh) |
| CA (1) | CA3035852A1 (zh) |
| CL (1) | CL2019001007A1 (zh) |
| IL (1) | IL265579A (zh) |
| JO (1) | JOP20190081A1 (zh) |
| MA (1) | MA46519A (zh) |
| MX (1) | MX2019004342A (zh) |
| PH (1) | PH12019500464A1 (zh) |
| RU (1) | RU2019113756A (zh) |
| SG (1) | SG11201901889QA (zh) |
| TW (1) | TW201817424A (zh) |
| WO (1) | WO2018069843A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070184A1 (en) * | 2015-10-20 | 2017-04-27 | Washington University In St. Louis | Mri method for in vivo detection of amyloid and pathology in the alzheimer brain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215884A1 (en) | 2004-02-27 | 2005-09-29 | Greicius Michael D | Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI |
| US9492114B2 (en) | 2004-06-18 | 2016-11-15 | Banner Health Systems, Inc. | Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease |
| EA024059B1 (ru) * | 2011-01-13 | 2016-08-31 | Новартис Аг | Гетероциклические производные и их применение в лечении неврологических расстройств |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| JOP20190003A1 (ar) | 2016-07-19 | 2019-01-10 | Novartis Ag | مشتق أوكسازين للاستخدام في الوقاية من مرض ألزهايمر في مرضى عُرضه للخطر |
-
2017
- 2017-06-16 JO JOP/2019/0081A patent/JOP20190081A1/ar unknown
- 2017-10-11 KR KR1020197012852A patent/KR20190068567A/ko not_active Application Discontinuation
- 2017-10-11 RU RU2019113756A patent/RU2019113756A/ru not_active Application Discontinuation
- 2017-10-11 JP JP2019519407A patent/JP2019534885A/ja active Pending
- 2017-10-11 CN CN201780060026.7A patent/CN109789145A/zh active Pending
- 2017-10-11 MX MX2019004342A patent/MX2019004342A/es unknown
- 2017-10-11 MA MA046519A patent/MA46519A/fr unknown
- 2017-10-11 AU AU2017342207A patent/AU2017342207B2/en not_active Ceased
- 2017-10-11 EP EP17787965.7A patent/EP3525793A1/en not_active Withdrawn
- 2017-10-11 CA CA3035852A patent/CA3035852A1/en not_active Abandoned
- 2017-10-11 SG SG11201901889QA patent/SG11201901889QA/en unknown
- 2017-10-11 BR BR112019006591A patent/BR112019006591A2/pt not_active IP Right Cessation
- 2017-10-11 TW TW106134647A patent/TW201817424A/zh unknown
- 2017-10-11 US US15/730,175 patent/US10722518B2/en active Active
- 2017-10-11 WO PCT/IB2017/056281 patent/WO2018069843A1/en unknown
-
2019
- 2019-03-01 PH PH12019500464A patent/PH12019500464A1/en unknown
- 2019-03-24 IL IL265579A patent/IL265579A/en unknown
- 2019-04-12 CL CL2019001007A patent/CL2019001007A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019113756A (ru) | 2020-11-13 |
| AU2017342207A1 (en) | 2019-03-21 |
| CL2019001007A1 (es) | 2019-06-21 |
| TW201817424A (zh) | 2018-05-16 |
| BR112019006591A2 (pt) | 2019-07-02 |
| US20180125853A1 (en) | 2018-05-10 |
| CA3035852A1 (en) | 2018-04-19 |
| AU2017342207B2 (en) | 2020-01-30 |
| IL265579A (en) | 2019-05-30 |
| MX2019004342A (es) | 2019-07-01 |
| WO2018069843A1 (en) | 2018-04-19 |
| US10722518B2 (en) | 2020-07-28 |
| RU2019113756A3 (zh) | 2021-03-05 |
| PH12019500464A1 (en) | 2019-11-25 |
| MA46519A (fr) | 2019-08-21 |
| WO2018069843A9 (en) | 2018-08-02 |
| KR20190068567A (ko) | 2019-06-18 |
| JOP20190081A1 (ar) | 2019-04-11 |
| CN109789145A (zh) | 2019-05-21 |
| EP3525793A1 (en) | 2019-08-21 |
| JP2019534885A (ja) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201901817SA (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201907217RA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809671PA (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
| SG11201806383TA (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| SG11201809494VA (en) | Pharmaceutical composition comprising eteplirsen | |
| SG11201806620TA (en) | Compositions and methods for treating infections | |
| SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration | |
| SG11201811022TA (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
| SG11201908870PA (en) | Methods of preventing or treating ophthalmic diseases |